NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 12, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2030

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Tiragolumab

600mg every 3 weeks (Q3W)

DRUG

Atezolizumab

1200mg every 3 weeks (Q3W)

DRUG

Ipilimumab

1 mg/kg, maximum of 4 cycles

Trial Locations (1)

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

All Listed Sponsors

collaborator

Hoffmann-La Roche

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER